A Pilot Randomized Controlled Trial of Adding Enfuvirtide to Standard Combination Antiretroviral Therapy in HIV-infected Individuals With Full Virologic Suppression to Further Suppress Proviral HIV DNA
A Pilot Randomized Controlled Trial of Adding Enfuvirtide to Standard Combination Antiretroviral Therapy in HIV-infected Individuals With Full Virologic Suppression to Further Suppress Proviral HIV DNA
In order to better understand the source(s) and the mechanism(s) of HIV persistence and to potentially lead to further suppression of HIV from viral reservoirs, we propose to examine the effect of co-administration of enfuvirtide, an entry inhibitor of HIV, on diminution of the size of the viral reservoir in infected individuals who are receiving effective antiviral therapy for extended periods of time (> 5 years).
Inclusion Criteria:
Exclusion Criteria:
Patient who would have difficulty participating in a trial due to non-adherence or substance abuse
Patient who have taken mono or dual antiretroviral therapy
Patient who have had a viral load > 50 copies/mL on any antiretroviral regimen
Patient with any of the following abnormal laboratory test results in screening:
Patient with a malignancy
Patient with other significant underlying disease (non-HIV) that might impinge upon disease progression or death
Patient with an active AIDS-defining illnesses in the past six months
Patients who are pregnant